Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06460298 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

StatusRecruiting
PhasePhase 1/2
Started2024-08-20
View on ClinicalTrials.gov ↗
This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer

Amendment history 2 changes detected by DataLookout

2026-09-01
Primary completion pushed: 2026-07-01 → 2027-07-01
2026-09-01
Completion pushed: 2026-10-01 → 2027-10-01
Trial Details
NCT Number NCT06460298
Lead Sponsor ProDa BioTech, LLC
Collaborators: Emory University, Georgia State University
Conditions Triple Negative Breast Cancer
Enrollment 51 participants
Start Date 2024-08-20
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-31